Next Article in Journal
Catena-[Triaquabis(μ2-1,4-bis(diphenylphosphoryl)butane)nitrato-κ2O-praseodymium(III)] Nitrate Monohydrate Methanol Solvate
Previous Article in Journal
3a-(4-Chlorophenyl)-1-thioxo-2,3,3a,4-tetrahydroimidazo[1,5-a]quinazolin-5(1H)-one
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Short Note

(E)-1-(2,4-Dinitrophenyl)-2-(2-((1R,3R,5S,Z)-2-ethylidene-6,6-dimethylbicyclo[3.1.1]heptan-3-yl)ethylidene)hydrazine

Department of Chemistry, Marquette University, P.O. Box 1881, Milwaukee, WI 53201-1881, USA
*
Author to whom correspondence should be addressed.
Current address: The State Key Laboratory of Elemento-Organic Chemistry, College of Chemistry, Nankai University, Tianjin 300071, China.
Molbank 2024, 2024(3), M1860; https://doi.org/10.3390/M1860
Submission received: 15 June 2024 / Revised: 14 July 2024 / Accepted: 17 July 2024 / Published: 30 July 2024
(This article belongs to the Section Organic Synthesis and Biosynthesis)

Abstract

:
The hydrovinylation of nopadiene gave a single 1,4-addition product (1) as an oil. A 3- step transformation of 3 gave 2,4-dinitrophenylhydrazone 6 as a crystalline compound. X-ray diffraction analysis of 6 confirmed the stereochemical assignments about the exocyclic olefin as well as at stereocenter C(3).

1. Introduction

Both β-pinene and myrtenal are chiral monoterpenes isolated from numerous terrestrial sources. While β-pinene is valued for its fragrance, myrtenal is an inhibitor of acetylcholinesterase [1]. Each of these monoterpenes can be used to prepare nopadiene, 1 [2,3]. Diene 1 is a starting material for the preparation of (1R)-9,9-dimethyltricyclo[6.1.1.02,6]deca-2,5-diene [4] which has been used to prepare a variety of transition metal complexes [5,6]. More recently, nopadiene has served as a chiral styrene substitute for elastomers [3].
The Ru-catalyzed hydrovinylation of nopadiene gave a single addition product (1) (Equation (1)) [7]. The structure of 3 was tentatively assigned based on its NMR spectral data, as well as based on the proposed structure of a π-allyl-Ru intermediate. To provide an unequivocal structural assignment, a crystalline 2,4-dinitrophenylhydrazone of 3 was prepared and its X-ray crystal structure was determined. While not the object of this study, some 2,4-dinitrophenylhydrazones have exhibited antifungal [8] and antimicrobial-resistant modulatory activity [9].
Molbank 2024 m1860 i001

2. Results and Discussion

2.1. Synthesis

Hydroboration of (+)-3 with 9-borobicyclo[3.3.1]nonane (9-BBN) followed by oxidation gave a primary alcohol (4, Scheme 1). Swern oxidation of 4 yielded aldehyde 5. Finally, reaction of 5 with 2,4-dinitrophenylhydrazine afforded the title compound, (+)-6 as a yellow solid (Scheme 1). The overall composition of 6 was identified by 1H and 13C NMR spectroscopy as well as combustion analysis.

2.2. Solid-State Structure

Recrystallization of the product from hot 95% ethanol gave yellow needles with a melting point of 143–145 °C. Figure 1 shows an ORTEP for each of the two unique structures in the unit cell, as determined by X-ray crystallography. Each of these molecules possesses the (Z)-stereochemistry of the exocyclic olefin and the (R)-configuration at the tertiary carbon adjacent to the exocyclic olefin. Notably, these stereochemical features of 6 corroborate the tentative structural assignment previously made for 3 [7]. The crystal belongs to the relatively rare triclinic, space group P1. There are significant conformational differences between two molecules within the unit cell with respect to certain torsional angles; the most striking difference is observed between C4–C12–C13–N1 = −14.8(4)° vs. C4A–C12A–C13A–N1A = −1.7(4)°. Due to these differences, the unit cell is chiral (in addition to each of the molecules being chiral, non-racemic).
The crystal packing for 6 is shown in Figure 2. There is intramolecular hydrogen bonding within a single molecule as well as intermolecular interactions between the two molecules (Table 1). Hydrogens were treated by a mixture of independent and constrained refinement. For this reason, the N2–H distance for N2–H2N is shorter than is usually observed. Both intramolecular [10,11,12,13,14,15,16] as well as intermolecular [17,18,19] hydrogen bonding in the crystalline state of 2,4-dinitrophenylhydrazones has been reported.

3. Materials and Methods

3.1. General

All 1H NMR and 13C NMR spectra were recorded at Varian 300 MHz spectrometer in CDCl3. 1H spectra were calibrated according to the residual signal of CHCl3 (δ 7.26 ppm) and 13C spectra were calibrated to the central peak for CDCl3 (δ 77.0 ppm). Optical rotations were recorded on a Perkin Elmer 341 optical polarimeter at 589 nm wavelength (20 °C). Melting points were obtained in open capillaries on a Mel-Temp melting point apparatus and were uncorrected. Elemental analysis was obtained from Midwest Microlabs, Ltd. (Indianapolis, IN, USA).
Crystal data for 6 were measured on a Bruker APEX2 diffractometer (Cu Kα radiation, CCD detector, ω-scanning). The structure was solved using the XS/SHELXTL v6.12 [20] and refined using SHELXL97 v. 97.2 [21] programs. Full-matrix least-squares refinement against F2 in anisotropic approximation was used for the non-hydrogen atoms. The weighted R-Factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. Hydrogens were treated by a mixture of independent and constrained refinement.
Crystal data: C19H24N4O4, a = 6.7643(2) Å, b = 8.3316(2) Å, c = 19.5719(6) Å, α = 79.330(2)o, β = 87.964(3)o, γ = 84.861(2)o, V = 949.84(5) Å3, triclinic, space group P1, Mr = 372.42, T = 100 K, Z = 2. R[F2 > 2σ(F2)] = 0.035, wR(F2) = 0.098, S = 1.00, Flack parameter = 0.2(2).
Final atomic coordinates, geometrical parameters, and crystallographic data have been deposited to the Cambridge Crystallographic Data Centre, 11 Union Road, Cambridge, CB2 1EZ, UK; URL accessed 23 July 2024 (https://www.ccdc.cam.ac.uk/structures/) and are available on request quoting the deposition number CCDC 1903584.

3.2. (1R,3R,5S,Z)2-(2-Ethylidene-6,6-dimethylbicyclo[3.1.1]hept-3-yl)ethanol (4)

To a solution of 3 (0.380 g, 2.16 mmol) in THF (15 mL) at room temperature under N2, was added a solution of 9-BBN (0.5 M in THF, 4.4 mL, 2.2 mmol). The reaction mixture was stirred for 18 h, and then 30% H2O2 (2.5 mL) was cautiously added followed by 1 M aqueous KOH (4.4 mL). The mixture was stirred for a further 30 min and partitioned between ether and brine and the organic extract was dried (Na2SO4) and concentrated. The residue was purified by column chromatography to afford 4 as a colorless oil (0.310 g, 74%). Rf = 0.35 (hexanes–ether = 2:1). 1H-NMR (300 MHz, CDCl3) δ = 5.26 (dq, J = 1.5, 6.0 Hz, 1H, C=CHMe), 3.80–3.65 (m, 2H, CH2OH), 2.84 (t, J = 5.7 Hz, 1H), 2.52–2.40 (m, 1H), 2.36–1.60 (m, 7H), 1.53 (dd, J = 1.0, 6.3 Hz, 3H, C=CHMe), 1.27 (s and m, 4H), 0.70 (s, 3H, CH3). 13C-NMR (75 MHz, CDCl3) δ = 145.6, 117.1, 61.4, 46.3, 44.5, 41.3, 40.7, 32.1, 31.2, 27.4, 26.1, 21.5, 12.6 ppm. Anal. Calcd for C13H22O (194.31): C, 80.36; H, 11.41. Found: C, 79.82; H, 11.05.

3.3. (1R,3R,5S,Z)(2-Ethylidene-6,6-dimethyl-bicyclo[3.1.1]hept-3-yl)acetaldehyde (5)

To a solution of DMSO (0.40 g, 5.1 mmol) in CH2Cl2 (20 mL) at −60 °C, was added dropwise a 2.0 M solution of oxalyl chloride (0.39 g, 3.1 mmol) in CH2Cl2 (10 mL). The mixture was stirred for 20 min and then a solution of 4 (0.45 g, 2.3 mmol) was added dropwise. The mixture was stirred for 10 min and then triethylamine (1.76 mL) was slowly added dropwise. The mixture was warmed to room temperature, stirred for 30 min and then quenched with water (10 mL). The mixture was extracted several times with CH2Cl2. The combined extracts were concentrated, and the crude product was dissolved in hexanes–ether (1:1), filtered and concentrated. The residue was purified by column chromatography (SiO2, hexanes–ethyl acetate, 10:1) to give 5 (0.38 g, 86%) as a colorless oil. Rf = 0.43 (hexanes–ether = 10:1). 1H-NMR (300 MHz, CDCl3) δ = 9.78 (t, J = 2.1 Hz, 1H), 5.24 (dq, J = 1.0, 6.7 Hz, 1H), 3.18–2.97 (m, 1H), 2.87 (t, J = 5.7 Hz, 1H), 2.80–2.63 (m, 2H), 2.43–2.20 (m, 3H), 2.20–1.95 (m, 1H), 1.53 (dd, J = 1.5, 6.9 Hz, 3H), 1.28 (s, 3H), 1.20 (d, J = 10.5 Hz, 1H), 0.74 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ = 202.6, 144.5, 117.8, 57.9, 44.6, 41.2, 40.3, 32.0, 29.6, 27.8, 26.1, 21.6, 12.6 ppm. Anal. Calcd for C13H20O (192.30): C, 81.20; H, 10.48. Found: C, 80.78; H, 10.31.

3.4. (E)-1-(2,4-Dinitrophenyl)-2-(2-((1R,3R,5S,Z)-2-ethylidene-6,6-dimethylbicyclo[3.1.1]heptan-3-yl)ethylidene)hydrazine (6)

Conc. HCl (1 mL) was added to a solution of 2,4-dinitrophenyl-hydrazine (0.50 g, 2.5 mmol) in 95% ethanol (12 mL). The mixture was heated to 80 °C for 10 min and then filtered through glass wool. A portion of this solution (4 mL) was added to a solution of 5 (0.15 g, 0.78 mmol) in 95% ethanol (2 mL) at 40 °C, where a yellow precipitate immediately began to form. After stirring for 30 min, the precipitate was collected by filtration and washed with 95% ethanol. The solid was recrystallized from hot 95% ethanol to afford 6 yellow needles (0.13 g, 44%). Mp 143–145 °C; [α]D20 = +4.6 (c = 0.5, CH2Cl2); 1H-NMR (300 MHz, CDCl3) δ = 11.06 (s, 1H, NH), 9.13 (d, J = 3.0 Hz, 1H, H-3 of DNP), 8.31 (dd, J = 2.7, 9.6 Hz, 1H, H-5 of DNP), 7.97 (d, J = 9.6 Hz, 1H, H-6 of DNP), 7.56 (t, J = 5.7 Hz, 1H, CH=N), 5.33 (q, J = 6.9 Hz, 1H, C=CHMe), 2.95–1.98 (m, 8H), 1.58 (dd, J = 0.6, 6.9 Hz, 3H, C=CHMe), 1.30 (s, 3H, Me-8), 1.26 (d, J = 9.9 Hz, 1H), 0.76 (s, 3H, Me-9). 13C-NMR (75 MHz, CDCl3) δ = 152.2 (C=N), 145.0 (C=CHCH3), 144.2 (C-1 of DNP), 137.6 (C-4 of DNP), 129.9 (C-2 of DNP), 128.7 (C-5 of DNP), 123.4 (C-3 of DNP), 118.2 (C=CHCH3), 116.5 (C-6 of DNP), 45.5, 44.6, 41.3, 40.5 (C-6), 33.2, 30.8, 27.9, 26.1 (C=CHCH3), 21.7 (CH3), 12.6 (CH3). Anal. Calcd for C19H24N4O4 (374.12): C, 61.28; H, 6.50; N, 15.04. Found: C, 61.25; H, 6.45; N, 15.00. (Supplementary Materials Figures S1 and S2).

Supplementary Materials

Figure S1: 1H NMR spectrum of 6; Figure S2: 13C NMR spectrum of 6.

Author Contributions

Conceptualization, W.A.D. and Z.H.; methodology, Z.H. and S.L.; validation, Z.H. and S.L.; formal analysis, S.L.; investigation, Z.H. and S.L.; resources, W.A.D.; data curation, W.A.D.; writing—original draft preparation, W.A.D.; writing—review and editing, W.A.D., Z.H. and S.L.; supervision, W.A.D.; project administration, W.A.D.; funding acquisition, W.A.D. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Institutes of Health, grant number GM42641.

Data Availability Statement

The data presented in this study are available on request from the corresponding author due to legal reasons.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Kaufmann, D.; Dogra, A.K.; Wink, M. Myrtenal inhibits acetylcholinesterase, a known Alzheimer target. J. Pharm. Pharmacol. 2011, 63, 1368–1371. [Google Scholar] [CrossRef] [PubMed]
  2. Wu, J.Y.; Moreau, B.; Ritter, T. Iron-Catalyzed 1,4-Hydroboration of 1,3-Dienes. J. Am. Chem. Soc. 2009, 131, 12915–12917. [Google Scholar] [CrossRef] [PubMed]
  3. Hahn, C.; Gottker-Schnetmann, I.; Tzourtzouklis, I.; Wagner, M.; Muller, A.H.E.; Floudas, G.; Mecking, S.; Frey, H. Nopadiene: A Pinene-Derived Cyclic Diene as a Styrene Substitute for Fully Biobased Thermoplastic Elastomers. J. Am. Chem. Soc. 2023, 145, 26688–26698. [Google Scholar] [CrossRef] [PubMed]
  4. Paquette, L.A.; McLaughlin, M.L. Cyclopentadiene annulation via the Skattebol rearrangement: (1R)-9,9-dimethyltricyclo-[6.1.1.02,6]deca-2,5-diene. Org. Syn. 1990, 68, 220. [Google Scholar]
  5. Paquette, L.A.; Moriarty, K.J.; Rogers, R.D. (1R)-(–)-Nopol as the Source of an Optially Pure Fused Cyclopentadienyl Ligand. Stereochemical Course of Complexation to Cyclopentadienyltitanium and -zirconium Dichloride Fragments. Organometallics 1989, 8, 1506–1511. [Google Scholar] [CrossRef]
  6. Halterman, R.L. Synthesis and Applications of Chiral Cyclopentadienylmetal Complexes. Chem. Rev. 1992, 92, 965–994. [Google Scholar] [CrossRef]
  7. He, Z.; Donaldson, W.A. (1R,3R,5S,Z)-2-Ethylidene-6,6-dimethyl-3-vinylbicyclo[3.1.1]-heptane. Molbank 2024, 2024, M1850. [Google Scholar] [CrossRef]
  8. Ortiz, S.; Nelson, R.; Kesternich, V.; Perez-Fehrmann, M.; Christen, P.; Marcourt, L. Synthesis and antifungal activity of diaryl hydrazones from 2,4-dinitrophenylhydrazine. J. Chil. Chem. Soc. 2016, 61, 3081–3084. [Google Scholar] [CrossRef]
  9. Ade, A.; Amengor, C.D.K.; Brobbey, A.; Ayensu, I.; Harley, B.K.; Boakye, Y.D. Synthesis and Antimicrobial Resistant Modulatory Activity of 2,4-Dinitrophenylhydrazone Derivatives as Agents against Some ESKAPE Human Pathogens. J. Chem. 2020, 2020, 2720697. [Google Scholar] [CrossRef]
  10. Han, H.; Liu, Y. A monoclinic polymorph with Z = 4 of (E)-2,4-dinitrophenylhydrazone N,N-dimethylformamide monosolvate. Acta Cryst. E 2011, 67, o3434. [Google Scholar] [CrossRef]
  11. Jasinski, J.P.; Guild, C.J.; Chidan Kumar, C.S.; Yathirajan, H.S.; Mayekar, A.N. (1e)-1-(3-Bromophenyl)ethenone 2,4-dinitrophenylhydrazone. Acta Cryst. E 2010, 66, o2832–o2833. [Google Scholar] [CrossRef] [PubMed]
  12. Zhao, L.-X.; Li, G.-S. Bis[4-hydroxy-3,5dimethoxybenzaldehyde (2,4-dinitrophenyl)hydrazone] N,N-dimethylformamide disolvate monohydrate. Acta Cryst. E 2010, 66, o2644. [Google Scholar] [CrossRef] [PubMed]
  13. Zhao, L.-X.; Li, G.-S. 5-Diethylamino-2-{[2-(2,4-dinitrophenyl)hydrazin-ylidene]methyl}phenol. Acta Cryst. E 2010, 66, o3108. [Google Scholar] [CrossRef] [PubMed]
  14. Ji, N.-N.; Shi, Z.-Q. 1-Cyclopentylidene-2-(2,4-dinitrophenyl)hydrazine. Acta Cryst. E 2008, 64, o2141. [Google Scholar] [CrossRef] [PubMed]
  15. Bao, F.-U. 2,4-Dichlorobenzaldehyde 2,4-dinitrophenylhydrazone. Acta Cryst. E 2008, 64, o1433. [Google Scholar] [CrossRef] [PubMed]
  16. Xin, Z.; Li, M.; Chen, Z.; Zhu, R. 1-(2,3-Dimethoxybenzylidene)-2-(2,4-dinitrophenyl)hydrazine. Acta Cryst. Sect. E 2011, 67, o1169. [Google Scholar] [CrossRef] [PubMed]
  17. Fun, H.-K.; Kia, R.; Kargar, H. 2-Methoxybenzaldehyde 2,4-dinitrophenylhydrazone. Acta Cryst. Sect. E 2009, 65, o246–o247. [Google Scholar] [CrossRef] [PubMed]
  18. Jasinski, J.P.; Braley, A.N.; Kumar, C.S.C.; Yathirajan, H.S.; Mayekar, A.N. (E)-1-(2,4-Dinitrophenyl)-2-(2-fluorobenzylidene)hydrazine. Acta Cryst. Sect. E 2011, 67, o1200–o1201. [Google Scholar] [CrossRef] [PubMed]
  19. Neunfeldt, P.D.; Duval, A.R.; Cunico, W.; Wardell, S.M.S.V.; Tiekink, E.R.T.; Wardell, J.L. (E)-1-(2,4-Dinitrophenyl)-2-pentenylidenehydrazine. Acta Cryst. E. 2010, 66, o483–o484. [Google Scholar] [CrossRef]
  20. Sheldrick, G.M. SHELXT–Integrated space-group and crystal structure determination. Acta Cryst. 2015, 71, 3–8. [Google Scholar] [CrossRef]
  21. Sheldrick, G.M. Crystal structure refinement with SHELXL. Acta Cryst. 2015, 71, 3–8. [Google Scholar]
Scheme 1. Synthesis of (+)-6. Atom numbering is arbitrary and corresponds to that assigned to the X-ray structure.
Scheme 1. Synthesis of (+)-6. Atom numbering is arbitrary and corresponds to that assigned to the X-ray structure.
Molbank 2024 m1860 sch001
Figure 1. ORTEP of each of the two unique molecules of (+)-6 in the unit cell [CCDC 1903584]. Atom numbering is arbitrary and does not correspond to numbering inherent in the IUPAC name of 6. While there are a number of differences between the two molecules with respect to torsional angles the most striking difference is observed between C4–C12–C13–N1 = −14.8(4)° and C4A–C12A–C13A–N1A = −1.7(4)°.
Figure 1. ORTEP of each of the two unique molecules of (+)-6 in the unit cell [CCDC 1903584]. Atom numbering is arbitrary and does not correspond to numbering inherent in the IUPAC name of 6. While there are a number of differences between the two molecules with respect to torsional angles the most striking difference is observed between C4–C12–C13–N1 = −14.8(4)° and C4A–C12A–C13A–N1A = −1.7(4)°.
Molbank 2024 m1860 g001
Figure 2. Crystal packing structure of (+)-6 [CCDC 1903584].
Figure 2. Crystal packing structure of (+)-6 [CCDC 1903584].
Molbank 2024 m1860 g002
Table 1. Hydrogen-bond geometry for 6.
Table 1. Hydrogen-bond geometry for 6.
D–HAD–HHADAD–HA
N2–H2NO10.79(4) Å2.07(4) Å2.617(3) Å127(3)°
N2–H2NO1A0.79(4) Å2.48(4) Å3.210(3) Å156(3)°
N2A–H2NAO1A0.89(4) Å2.06(4) Å2.624(3) Å120(3)°
N2A–H2NAO10.89(4) Å2.45(4) Å3.301(3) Å161(3)°
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

He, Z.; Lindeman, S.; Donaldson, W.A. (E)-1-(2,4-Dinitrophenyl)-2-(2-((1R,3R,5S,Z)-2-ethylidene-6,6-dimethylbicyclo[3.1.1]heptan-3-yl)ethylidene)hydrazine. Molbank 2024, 2024, M1860. https://doi.org/10.3390/M1860

AMA Style

He Z, Lindeman S, Donaldson WA. (E)-1-(2,4-Dinitrophenyl)-2-(2-((1R,3R,5S,Z)-2-ethylidene-6,6-dimethylbicyclo[3.1.1]heptan-3-yl)ethylidene)hydrazine. Molbank. 2024; 2024(3):M1860. https://doi.org/10.3390/M1860

Chicago/Turabian Style

He, Zhengjie, Sergey Lindeman, and William A. Donaldson. 2024. "(E)-1-(2,4-Dinitrophenyl)-2-(2-((1R,3R,5S,Z)-2-ethylidene-6,6-dimethylbicyclo[3.1.1]heptan-3-yl)ethylidene)hydrazine" Molbank 2024, no. 3: M1860. https://doi.org/10.3390/M1860

APA Style

He, Z., Lindeman, S., & Donaldson, W. A. (2024). (E)-1-(2,4-Dinitrophenyl)-2-(2-((1R,3R,5S,Z)-2-ethylidene-6,6-dimethylbicyclo[3.1.1]heptan-3-yl)ethylidene)hydrazine. Molbank, 2024(3), M1860. https://doi.org/10.3390/M1860

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop